Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Apr. 26, 2024)

View and export this data going back to 1996. Start your Free Trial

What is Spectrum Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-04-26), Spectrum Pharmaceuticals's share price is $1.03. Spectrum Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.46. Hence, Spectrum Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Spectrum Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, Spectrum Pharmaceuticals's highest Price-to-Operating-Cash-Flow Ratio was 97.44. The lowest was 0.00. And the median was 13.55.

SPPI's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.725
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Spectrum Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Mar. 2023 was $-0.11. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.46.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 24.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -3.70% per year.

During the past 13 years, Spectrum Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 75.90% per year. The lowest was -153.80% per year. And the median was 13.80% per year.

Spectrum Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Spectrum Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectrum Pharmaceuticals Price-to-Operating-Cash-Flow Chart

Spectrum Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Spectrum Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Spectrum Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Spectrum Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spectrum Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spectrum Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Spectrum Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Spectrum Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

Spectrum Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	1.03	/	-0.462
	=

Spectrum Pharmaceuticals's Share Price of today is $1.03.
Spectrum Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.46.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Spectrum Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Spectrum Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spectrum Pharmaceuticals Inc (NAS:SPPI) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

Pilot House - Lewis Wharf, 2 Atlantic Avenue, 6th Floor, Boston, MA, USA, 02110

Website

https://www.sppirx.com

Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations. It has one segment that is focused exclusively on developing and marketing oncology and hematology drug products.

Executives

Juhyun Lim	director	11500 S. EASTERN AVE., SUITE 220, HENDERSON NV 89052
Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Brittany Bradrick	director	C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Nora Brennan	officer: See Remarks	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Keith M Mcgahan	officer: Chief Legal Officer	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Thomas J Riga	director, officer: CEO & President	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Jeff L Vacirca	director	4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Francois Lebel	officer: Chief Medical Officer	4100 LEXINGTO AVE N, ARDEN HILLS MN 55126-2998
Dolatrai Vyas	director	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Kurt A Gustafson	officer: EVP & Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Joseph W. Turgeon	officer: Chief Commercial Officer	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Elizabeth Czerepak	director	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Maida Anthony E Iii	director	157 TECHNOLOGY DR, IRVINE CA 92618
Stuart Mitchell Krassner	director	157 TEHCNOLOGY DRIVE, IRVINE CA 92618